GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » EV-to-EBITDA

Biocept (FRA:B00) EV-to-EBITDA : -0.20 (As of May. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biocept EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biocept's enterprise value is €5.54 Mil. Biocept's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was €-27.61 Mil. Therefore, Biocept's EV-to-EBITDA for today is -0.20.

The historical rank and industry rank for Biocept's EV-to-EBITDA or its related term are showing as below:

FRA:B00' s EV-to-EBITDA Range Over the Past 10 Years
Min: -85.7   Med: -0.77   Max: 12.73
Current: -0.17

During the past 12 years, the highest EV-to-EBITDA of Biocept was 12.73. The lowest was -85.70. And the median was -0.77.

FRA:B00's EV-to-EBITDA is ranked worse than
100% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.3 vs FRA:B00: -0.17

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Biocept's stock price is €6.80. Biocept's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-49.041. Therefore, Biocept's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Biocept EV-to-EBITDA Historical Data

The historical data trend for Biocept's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept EV-to-EBITDA Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.37 -3.46 -50.97 -0.27

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.43 -0.27 -0.31 -0.27

Competitive Comparison of Biocept's EV-to-EBITDA

For the Diagnostics & Research subindustry, Biocept's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biocept's EV-to-EBITDA falls into.



Biocept EV-to-EBITDA Calculation

Biocept's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5.539/-27.608
=-0.20

Biocept's current Enterprise Value is €5.54 Mil.
Biocept's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-27.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept  (FRA:B00) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biocept's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.80/-49.041
=At Loss

Biocept's share price for today is €6.80.
Biocept's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.041.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Biocept EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biocept's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (FRA:B00) Business Description

Traded in Other Exchanges
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines